Teduglutide

Teduglutide is a 33-amino-acid recombinant analog of human glucagon-like peptide-2 (GLP-2). The structural modification is a glycine-for-alanine substitution at position 2 of the native GLP-2 sequence, which protects against rapid degradation by dipeptidyl peptidase IV (DPP-IV) and extends the plasma half-life from approximately 7 minutes (native GLP-2) to approximately 3 hours. It is administered as once-daily subcutaneous injection at 0.05 mg/kg in adults and pediatric patients aged 1 year and older. It is marketed as Gattex by Takeda Pharmaceuticals (Revestive in the EU). The approved indication is short bowel syndrome (SBS) in patients dependent on parenteral support.

The molecule was developed by NPS Pharmaceuticals based on the recognition that GLP-2 is an endogenous intestinotrophic hormone secreted by intestinal L-cells in response to nutrient intake. GLP-2 produces intestinal mucosal growth, increases nutrient and fluid absorption, and supports intestinal blood flow. These effects are mechanistically relevant for short bowel syndrome, where surgical removal of small intestine produces inadequate nutrient absorption and dependence on parenteral nutrition.

FDA orphan drug designation was granted in 2000. The pivotal Phase 3 clinical program completed in 2010-2012 with FDA approval on December 21, 2012 for adults. The pediatric indication (ages 1 and older) was approved on May 17, 2019. NPS Pharmaceuticals was acquired by Shire in 2015, and Shire was later acquired by Takeda in 2019.

The clinical use is narrow but clinically meaningful for SBS patients. Approximately 10,000 to 20,000 patients in the United States have SBS severe enough to require chronic parenteral support, and teduglutide is the only pharmacotherapy that has consistently reduced parenteral support requirements in this population.

The Clinical Evidence

The teduglutide clinical-trial program is the most substantial for any SBS pharmacotherapy.

STEPS Phase 3 trial. The pivotal trial supporting the 2012 approval. 86 adult SBS patients on stable parenteral support randomized to teduglutide 0.05 mg/kg daily or placebo for 24 weeks. The primary endpoint was the proportion of patients achieving 20 percent or greater reduction in weekly parenteral support volume at weeks 20 and 24. Teduglutide produced response in approximately 63 percent of patients versus 30 percent of placebo patients.

STEPS 2 extension. 24-month open-label extension that enrolled patients from STEPS and additional patients. The longer-term data showed that approximately 14 percent of patients achieved complete weaning from parenteral support during the extended treatment period, a level of response that has not been replicated by any other SBS pharmacotherapy.

STEPS 3. Additional Phase 3 trial supporting the regulatory program. Confirmed the efficacy findings of STEPS and STEPS 2.

Pediatric trials. Phase 3 trials in pediatric SBS patients aged 1 to 17 years supported the May 2019 pediatric approval. Pediatric efficacy was similar to adult efficacy, with reduced parenteral support requirements and some patients achieving complete weaning.

Total clinical program. 566 subjects were treated with teduglutide across the development program. 173 SBS subjects participated in efficacy and safety studies. 97 SBS subjects had at least 12 months of exposure.

The clinical evidence base is the strongest for any SBS pharmacotherapy and represents one of the most thorough orphan drug development programs in recent FDA history.

Teduglutide acts on the GLP-2 receptor (GLP-2R), which is expressed primarily on enteroendocrine cells, subepithelial myofibroblasts, and enteric neurons in the intestinal mucosa.

Intestinal mucosal growth. GLP-2R activation drives proliferation of intestinal epithelial cells and increases villus height in the small intestine. The increased absorptive surface area is the central mechanism for improved nutrient and fluid absorption in SBS.

Slowed gastric emptying. GLP-2R activation reduces gastric motility, increasing the time available for nutrient absorption in the remaining small intestine.

Reduced gastric secretions. Reduced gastric acid and gastric volume output. This is particularly relevant for SBS patients who often have high-output stomas or losses through severely shortened intestine.

Increased intestinal blood flow. Mesenteric vasodilation increases intestinal blood flow and may support nutrient transport across the absorptive epithelium.

Reduced intestinal permeability. Strengthened mucosal barrier function reduces fluid losses from the intestine.

Trophic effects on the colon. GLP-2R is also expressed in the colon, where activation produces mucosal proliferation. This is the basis for the colorectal polyp warning in the labeling (sustained mucosal proliferation has theoretical neoplastic implications).

The combined effects support intestinal adaptation and improve net absorption of nutrients and fluids, reducing the volume of parenteral support required to maintain adequate nutrition.

Regulatory status

United States. FDA-approved December 21, 2012 for adults. Pediatric approval (ages 1 and older) on May 17, 2019. Indication is short bowel syndrome in patients dependent on parenteral support.

EU. EMA approval as Revestive (the EU brand name). The same indication and dosing.

Other markets. Approved in essentially all major regulatory jurisdictions for the SBS indication.

Pricing. Teduglutide is among the most expensive specialty medications. Annual cost can exceed $300,000 to $400,000 depending on patient weight (the 0.05 mg/kg dosing scales with body weight). The high pricing is justified by the rare indication and the dramatic clinical benefit (reduction or elimination of parenteral nutrition that itself costs $100,000 to $200,000 annually).

Distribution. Specialty pharmacy distribution only. Pediatric gastroenterologists and adult intestinal failure specialists prescribe and monitor treatment.

WADA status. Teduglutide is not currently on the WADA Prohibited List. The compound is not positioned as performance-enhancing.

Dosing protocols and literature-reported ranges are documented in the approved label or trial publications referenced above.

The teduglutide safety profile is well characterized through the trial program and post-marketing experience.

Colorectal polyps. The most clinically significant safety concern. GLP-2 receptor activation produces mucosal proliferation in the colon as well as the small intestine. The labeling includes a warning for acceleration of neoplastic growth. Patients require pre-treatment colonoscopy and periodic surveillance colonoscopy (typically annually for the first year, then less frequently if no polyps are identified).

Acceleration of polyp growth. Patients with existing polyps may have accelerated polyp growth on teduglutide. Pre-treatment polyp removal is standard.

Gastrointestinal effects. Abdominal pain, nausea, abdominal distension, and stomal complications are common. Generally manageable but require monitoring.

Cholecystitis and cholelithiasis. Gallbladder disease occurs at low rates.

Pancreatitis. Rare but reported.

Intestinal obstruction. Particularly in patients with anatomic predisposition.

Injection-site reactions. Common with subcutaneous administration. Generally mild.

Fluid retention. Mild to moderate, often manageable.

The safety profile is generally favorable for the SBS indication where the benefit (reduced parenteral support) substantially outweighs the manageable risks. The colorectal polyp warning is the central long-term safety consideration.

The GLP-2 analog class has remained limited.

Teduglutide. The only FDA-approved GLP-2 analog. Once-daily dosing. Approved for SBS.

Glepaglutide (apraglutide). Long-acting GLP-2 analog developed by Ironwood Pharmaceuticals and Zealand Pharma (different program). Once-weekly dosing. In Phase 3 development for SBS. Not yet FDA-approved.

Native GLP-2. Not viable as therapeutic due to rapid degradation. The teduglutide molecular design (Gly-2 substitution) is what enables clinical use of the GLP-2 mechanism.

For practical positioning in 2026, teduglutide remains the only approved GLP-2 analog for SBS. The Phase 3 development of glepaglutide and other long-acting analogs may expand options in coming years with the convenience advantage of less frequent dosing.